We are preparing the requested document. Please wait, this may take a while...!
|Antigen||V-Myc Myelocytomatosis Viral Oncogene Homolog (Avian) (MYC) Antibodies|
|Epitope||AA 200-250, N-Term Alternatives|
|Reactivity||Cat (Feline), Human, Monkey Alternatives|
|Conjugate||This C-MYC antibody is un-conjugated Alternatives|
Immunoprecipitation (IP), ELISA, Western Blotting (WB)
|Supplier||Log in to see|
Product Details anti-C-MYC AntibodyTarget Details C-MYC Application Details Handling Images
|Blocking Peptide||Blocking peptide for this product available: ABIN2749442|
|Cross-Reactivity||Rat (Rattus), Mouse (Murine)|
|Cross-Reactivity (Details)||The antibody does not cross react to any other cellular protein.|
|Characteristics||cMyc selective antibodies were generated against a peptide taken from the human protein. The cMyc-selective antibodies are affinity purified on an immobilized antigen based affinity matrix, the isolated antibodies were then stabilized in antibody stabilization buffer for long-term storage. The cMyc-selective antibodies are fully characterized for applications in western blotting and ELISA at the recommended dilutions. The supplier provides cMyc Western blot positive control samples in SDS-PAGE sample buffer.|
|Immunogen||Synthetic peptide taken within amino acid region 200-250 on human cMyc protein.|
Target Details C-MYCProduct Details anti-C-MYC Antibody Application Details Handling Images back to top
|Alternative Name||C-Myc (MYC Antibody Abstract)|
|Background||Myc genes are a family of proto-oncogenes (L- Myc, N- Myc and C- Myc) which are transcription factors implicated in cellular proliferation, cellular transformation, differentiation, apoptosis, metabolism, adhesion and self-renovation of tumor stem cells. Myc protein acts as transcriptional activator/repressor, and is activated via response to diverse mitogenic signals (including Wnt, Shh and EGF). These proteins share a common basic-helix-loop-helix leucine zipper (bHLH-ZIP) motif required for dimerization and DNA-binding. Myc proteins are nuclear proteins with relatively short half-lives and play a central role as both a key target and a cooperating transcription factor to drive oncogenic growth and is up-regulated in several types of cancers. The cMyc protein is a 55 kDa nuclear factor ubiquitously expressed in the nucleus and is the prototype for oncogene activation by chromosomal translocation. Mutations, overexpression, rearrangement and translocation of this gene are associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt's lymphoma. In Burkitt's lymphomas, the removal or specific mutation of exon 1 in cMyc translocations correlates with suppression of synthesis of the larger protein, and thus contributes to the oncogenic activation of c-myc. cMyc activates the transcription of growth-related genes and its overexpression induces cell-cycle progression thereby implicating in a variety of cancers. Amplification of the c-Myc gene is found in several types of human tumors including lung, breast and colon carcinoma. C-Myc is modified by glycosylation and phosphorylation, and interacts with a number of proteins including SMAD2, SMAD3, Pam, cdc6, BRCA1, Mlh1, p34cdc2, MAD, and Sp1. cMyc is extremely labile and is degraded very quickly even in extracts prepared with boiling SDS sample buffer. c-Myc participates in gene transcription regulation and binds DNA in a non-specific manner, specifically recognizing core sequence 5'-CAC[GA]TG-3'. The gene for cMyc is present on chromosome 8q24.21.|
|Research Area||Transcription Factors|
|Pathways||p53 Signaling, Cell Division Cycle, Sensory Perception of Sound, Transition Metal Ion Homeostasis, Mitotic G1-G1/S Phases, Positive Regulation of Endopeptidase Activity, Regulation of Carbohydrate Metabolic Process, Positive Regulation of Response to DNA Damage Stimulus|
Application DetailsProduct Details anti-C-MYC Antibody Target Details C-MYC Handling Images back to top
Antibodies were tested in ELISA and western blotting applications at 1:500 dilution using ABIN1686561 samples. Antibody dilutions for these antibodies are for reference only, investigators are expected to determine the optimal conditions. Application of this antibody in other protocols has not yet tested.
WB: > 1:500
IMM & IP pull-down assays: n.d.
Investigators using this antibody in protocols other than listed above can request a complimentary sample of this antibody. n.d. not necessarily means the antibody is not suitable for that application, it simply means we have not yet characterized the antibody for that application.
The antibody labels a strong band of cMyc at 55 kDa in ABIN1686561 samples and in other cancer cell lines.
|Restrictions||For Research Use only|
HandlingProduct Details anti-C-MYC Antibody Target Details C-MYC Application Details Images back to top
|Storage Comment||Storage of very dilute antibody solutions is not recommended.|